|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UHRF2 |
Gene summary for UHRF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UHRF2 | Gene ID | 115426 |
| Gene name | ubiquitin like with PHD and ring finger domains 2 | |
| Gene Alias | NIRF | |
| Cytomap | 9p24.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96PU4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 115426 | UHRF2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.41e-07 | -3.11e-01 | 0.0155 |
| 115426 | UHRF2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.88e-06 | -2.99e-01 | 0.0674 |
| 115426 | UHRF2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.90e-06 | -2.87e-01 | 0.3005 |
| 115426 | UHRF2 | A015-C-203 | Human | Colorectum | FAP | 2.03e-35 | 6.55e-01 | -0.1294 |
| 115426 | UHRF2 | A015-C-204 | Human | Colorectum | FAP | 3.05e-04 | 3.02e-01 | -0.0228 |
| 115426 | UHRF2 | A014-C-040 | Human | Colorectum | FAP | 8.25e-08 | 6.27e-01 | -0.1184 |
| 115426 | UHRF2 | A002-C-201 | Human | Colorectum | FAP | 3.42e-13 | 4.52e-01 | 0.0324 |
| 115426 | UHRF2 | A001-C-108 | Human | Colorectum | FAP | 6.99e-09 | -1.98e-02 | -0.0272 |
| 115426 | UHRF2 | A002-C-205 | Human | Colorectum | FAP | 1.20e-14 | 1.43e-01 | -0.1236 |
| 115426 | UHRF2 | A015-C-006 | Human | Colorectum | FAP | 1.15e-07 | -6.43e-03 | -0.0994 |
| 115426 | UHRF2 | A015-C-106 | Human | Colorectum | FAP | 1.32e-06 | -2.05e-03 | -0.0511 |
| 115426 | UHRF2 | A002-C-114 | Human | Colorectum | FAP | 4.89e-10 | -3.88e-02 | -0.1561 |
| 115426 | UHRF2 | A015-C-104 | Human | Colorectum | FAP | 1.66e-21 | 1.67e-01 | -0.1899 |
| 115426 | UHRF2 | A001-C-014 | Human | Colorectum | FAP | 1.32e-06 | -2.98e-02 | 0.0135 |
| 115426 | UHRF2 | A002-C-016 | Human | Colorectum | FAP | 4.68e-12 | -5.01e-02 | 0.0521 |
| 115426 | UHRF2 | A015-C-002 | Human | Colorectum | FAP | 4.09e-05 | -5.88e-02 | -0.0763 |
| 115426 | UHRF2 | A001-C-203 | Human | Colorectum | FAP | 1.25e-06 | 1.27e-02 | -0.0481 |
| 115426 | UHRF2 | A002-C-116 | Human | Colorectum | FAP | 6.65e-36 | 4.39e-01 | -0.0452 |
| 115426 | UHRF2 | A014-C-008 | Human | Colorectum | FAP | 1.38e-05 | -1.52e-01 | -0.191 |
| 115426 | UHRF2 | A018-E-020 | Human | Colorectum | FAP | 5.42e-11 | -6.77e-02 | -0.2034 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051865 | Colorectum | AD | protein autoubiquitination | 28/3918 | 73/18723 | 4.87e-04 | 5.30e-03 | 28 |
| GO:00518651 | Colorectum | MSS | protein autoubiquitination | 25/3467 | 73/18723 | 1.00e-03 | 1.00e-02 | 25 |
| GO:00518652 | Colorectum | FAP | protein autoubiquitination | 22/2622 | 73/18723 | 2.88e-04 | 3.77e-03 | 22 |
| GO:00518653 | Colorectum | CRC | protein autoubiquitination | 18/2078 | 73/18723 | 8.33e-04 | 1.04e-02 | 18 |
| GO:00182059 | Thyroid | PTC | peptidyl-lysine modification | 188/5968 | 376/18723 | 1.34e-13 | 7.09e-12 | 188 |
| GO:00518659 | Thyroid | PTC | protein autoubiquitination | 40/5968 | 73/18723 | 4.17e-05 | 3.80e-04 | 40 |
| GO:00169256 | Thyroid | PTC | protein sumoylation | 30/5968 | 53/18723 | 1.71e-04 | 1.31e-03 | 30 |
| GO:001820516 | Thyroid | ATC | peptidyl-lysine modification | 193/6293 | 376/18723 | 6.92e-13 | 3.06e-11 | 193 |
| GO:005186513 | Thyroid | ATC | protein autoubiquitination | 41/6293 | 73/18723 | 6.14e-05 | 4.69e-04 | 41 |
| GO:001692513 | Thyroid | ATC | protein sumoylation | 30/6293 | 53/18723 | 4.84e-04 | 2.83e-03 | 30 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UHRF2 | SNV | Missense_Mutation | c.316G>C | p.Gly106Arg | p.G106R | Q96PU4 | protein_coding | tolerated(0.05) | benign(0.031) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| UHRF2 | SNV | Missense_Mutation | c.862G>A | p.Gly288Arg | p.G288R | Q96PU4 | protein_coding | deleterious(0.01) | benign(0.26) | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UHRF2 | SNV | Missense_Mutation | novel | c.1819N>T | p.Arg607Cys | p.R607C | Q96PU4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66J-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UHRF2 | deletion | In_Frame_Del | rs773686803 | c.1482_1487delNNNNNN | p.Phe495_Ala496del | p.F495_A496del | Q96PU4 | protein_coding | TCGA-AQ-A1H3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | ||
| UHRF2 | deletion | In_Frame_Del | rs773686803 | c.1482_1487delNNNNNN | p.Phe495_Ala496del | p.F495_A496del | Q96PU4 | protein_coding | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| UHRF2 | SNV | Missense_Mutation | novel | c.641N>G | p.Asp214Gly | p.D214G | Q96PU4 | protein_coding | deleterious(0.04) | probably_damaging(0.978) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UHRF2 | SNV | Missense_Mutation | novel | c.2396N>A | p.Ser799Asn | p.S799N | Q96PU4 | protein_coding | tolerated(0.62) | benign(0.068) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UHRF2 | SNV | Missense_Mutation | novel | c.1876G>C | p.Glu626Gln | p.E626Q | Q96PU4 | protein_coding | tolerated(0.12) | benign(0.302) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| UHRF2 | SNV | Missense_Mutation | c.251C>G | p.Ser84Cys | p.S84C | Q96PU4 | protein_coding | deleterious(0.03) | possibly_damaging(0.76) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| UHRF2 | SNV | Missense_Mutation | c.584C>T | p.Thr195Met | p.T195M | Q96PU4 | protein_coding | deleterious(0.02) | probably_damaging(0.971) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |